The benefits of fluorescence lifetime (FLT)-based technologies have been highlighted for more than a decade but thus far they have failed to gain widespread acceptance. Significant improvements in assay reagents and availability of HTS-compatible readers, however, have now delivered a cost-effective, robust technology applicable to a broad range of therapeutic targets. This article charts FLT development to be a highly attractive tool for drug discovery.
Fluorescence lifetime (FLT) largely failed to make a significant inroad as a screening technology when it was first introduced nearly a decade ago, despite the fact that intrinsically it has many benefits, particularly in dealing with assay interferences. Market studies undertaken in the intervening period have consistently uncovered a latent appetite within drug discovery for FLT assays.